Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-17
2006-10-17
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S241000, C514S248000, C514S252020, C514S252110, C514S255050, C514S266200, C514S275000, C544S120000, C544S122000, C544S180000, C544S237000, C544S238000, C544S284000, C544S295000, C544S296000, C544S331000, C544S332000
Reexamination Certificate
active
07122544
ABSTRACT:
Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure:wherein R1and R6are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.
REFERENCES:
patent: 4788195 (1988-11-01), Torley et al.
patent: 4876252 (1989-10-01), Torley et al.
patent: 4966622 (1990-10-01), Rempfler et al.
patent: 4973690 (1990-11-01), Rempfler et al.
patent: 5159078 (1992-10-01), Rempfler et al.
patent: 5166047 (1992-11-01), Hioki et al.
patent: 5262527 (1993-11-01), Gregory et al.
patent: 5489505 (1996-02-01), Kato et al.
patent: 5516775 (1996-05-01), Zimmerman et al.
patent: 5527914 (1996-06-01), Hioli et al.
patent: 5942384 (1999-08-01), Arai et al.
patent: 6114333 (2000-09-01), Davis et al.
patent: 6552029 (2003-04-01), Davis et al.
patent: 6693108 (2004-02-01), Green et al.
patent: WO 93/08167 (1993-04-01), None
patent: WO 98/18782 (1998-05-01), None
patent: WO 98/20003 (1998-05-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/53927 (1999-10-01), None
patent: WO 99/63821 (1999-12-01), None
patent: WO 00/12486 (2000-03-01), None
patent: WO 00/15657 (2000-03-01), None
patent: WO 00/31087 (2000-06-01), None
patent: WO 00/33844 (2000-06-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 00/43373 (2000-07-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/75118 (2000-12-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/14375 (2001-03-01), None
patent: WO 01/23382 (2001-04-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/91749 (2001-12-01), None
patent: WO 02/46170 (2002-06-01), None
patent: WO 02/085396 (2002-10-01), None
Green et al., Chemical Abstracts, vol. 134:178569, 2001.
Davis et al., Chemical Abstracts, vol. 129:4655, 1998.
Torley et al., Chemical Abstracts, vol. 108:112478, 1988.
Beg et al., “Embryonic lethality and liver degeneration in mice lacking the ReIA component of NF-kappa B”, Nature 376(6536):167-70.
Bohrer et al., 1997, “Role of NFkappaB in the mortality of sepsis.”,J. Clin. Inv. 100:972-985.
Brand et al., 1997, “Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion”,J Clin Inv. 97:1715-1722.
Burke et al. 1999, “Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epsilon as probes of the two catalytic subunits of IkappaB kinase, IKK-1 and IKK-2”,Journal of Biological Chemistry274:36145-36152.
Chen et al., 1996, “Activation and inhibition of the AP-1 complex in human breast cancer cells”,Mol. Carcinogenesis15:215-226.
Cramer et al., 1999, “A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappaB complex”,Structure7:R1-R6.
Deacon et al., 1999, “MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases”,J. Biol. Chem.274:16604-16610.
Delhase et al., 1999, “Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation”,Science284:309 313.
Dong et al., 1998, “Defective T cell differentiation in the absence of Jnk1”,Science282:2092-2095.
Farls et al., 1996, “Regulation of interleukin-2 transcription by inducible stabile expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinasein Jurkat T cells”,J. Biol. Chem.271:27366-27373.
Gosset et al., 1995, “Expression of E-selectin, 1CAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients”,Int Arch Allergy Immunol.106:69-77.
Gum et al., 1997, “Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades”,Oncogene14:1481-1493.
Han et al., 1999, “Jun N-terminal kinase in rheumatoid arthritis”,J. Pharm. Exp. Therap.291:124-130.
Hibi et al., 1993, “Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates thec-Junacitvation domain”,M. Genes Dev.7:2135-2148.
Hu et al., 1999, “Abnormal morphogeneis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase”,Science284:316-320.
Ishizuka et al., 1997, “Mast cell tumor necrosis factor alpha production is regulated by MEK kinases”,Proc. Nat. Acad. Sci. USA94:6358-6363.
Karin et al., 1997, “AP-1 function and regulation”,Curr Opin Cell Biol9:240-246.
Koch et al., 1995, “Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1”,Nature376:517-519.
Lange-Carter et al., 1993, “A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.”,Science260:315-319.
Li et al., 1996, “The Ras-JNK pathway is involved in shear-induced gene expression”,Mol. Cell. Biol.16:5947-5954.
Li et al., 1999, “IKK1-deficient mice exhibit abnormal development of skin and skeleton”,Genes&Development13:1322-1328.
Li et al., 1999, “Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.”,Science284:321-324.
Li et al., 1996, “Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+T cells”,Science271:1272-1276.
Lin et al., 1995, “Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2”,Science268:286-289.
Malinin et al., 1997, MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1,Nature385:540-544.
Mercurio et al., 1999, “IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex”,Mol Cell Biol.19:1526-1538.
Mercurio et al., 1997, “IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation”,Science278:860-866.
Milne et al., 1995, “p53 is phosphorylatedin vitroandin vivoby an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1”,J. Biol. Chem. 270:5511-5518.
Mohit et al., 1995, “p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system”, C.A.Neuron14:67-75.
Okamoto et al., 1997, “Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synovlocytes”,Arth&Rheum40:919-926.
Panes et al., 1995, “Regional differences in constitutive and Induced ICAM-1 expression in vivo”,Am J Physiol. 269:H1955-H1964.
Peet and Li, 1999, “kappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin”,Journal of Biological Chemistry274:32655-32661.
Pombo et al., 1994, “The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion”,J. Biol. Chem. 26 :26546-26551.
Raitano et al., 1995, “TheBcr-Ablleukemia oncogene activates Jun kinase and requires Jun for transformation”,Proc. Nat. Acad. Sci USA92:11746-11750.
Sabapathy et al., 1999, “JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development”,Curr Biol9:116-125.
Su et al., 1994, “JNK is involved in signal Integration during costimulation of T lymphocytes”,Cell77:727-736.
Swantek et al., 1997, “Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK”,Mol. Cell. Biol. 17:6274-6282.
Szabo et al., “Altered
Bhagwat Shripad S.
Erdman Paul E.
Kois Adam
MacFarlane Karen J.
Palanki Moorthy S. S.
Raymond Richard L.
Signal Pharmaceuticals LLC
LandOfFree
Anilinopyrimidine derivatives as IKK inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anilinopyrimidine derivatives as IKK inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anilinopyrimidine derivatives as IKK inhibitors and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3700545